EPCAM and prostate cancer: A completed phase I study in hormone-resistant prostate cancer patients has shown that the human antibody was well tolerated at all doses tested, has not reached a maximum tolerated dose at 6 mgkg−1, and showed no signs of pancreatitis, which had been an issue with two high-affinity anti-EpCAM mAbs.